SCHEMBL7168113

SCHEMBL7168113

CC(C)c1cc(/C=C(\C#N)C(=S)CCCc2ccccc2)cc(C(C)C)c1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
KDR P35968 1/20 0.66
EGFR P00533 7/20 0.50
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
TDP1 Q9NUW8 4/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 3/20 0.41
HPGD P15428 3/20 0.41
ALOX15 P16050 3/20 0.41
ALOX12 P18054 3/20 0.41
MAPK1 P28482 3/20 0.41
RECQL P46063 3/20 0.41
BLM P54132 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ERBB2 P04626 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7168120 1.00 MAPT (0.66) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL7168119 1.00 MAPT (0.66) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL5362540 0.84 MAPT (0.78) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL5362536 0.84 MAPT (0.78) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL5362544 0.84 MAPT (0.78) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL1371456 0.80 MAPT (1.00) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL1371460 0.80 MAPT (1.00) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL1371458 0.80 MAPT (1.00) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL5373092 0.74 MAPT (0.67) MAPTSMN1; SMN2KDREGFRKMT2A
SCHEMBL5373095 0.74 MAPT (0.67) MAPTSMN1; SMN2KDREGFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596878-B2 Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) 2003-07-22 US claimed